Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1071 | Pituitary - Clinical | ECE2017

Surgery versus expectant observation in clinically non-functioning pituitary adenomas – a 20-year single centre experience

Matta-Coelho Claudia , Almeida Rui , Marques Olinda

Background: Clinically non-functioning pituitary adenomas (NFPAs) are among the most common pituitary lesions. Its management includes surgery, radiation or observation. The authors aim to compare clinical characteristics and outcomes between patients submitted to surgery or expectant observation (EO).Methods: Retrospective review of medical records from 1996 to 2016. In our centre, there is only 1 pituitary surgeon and NFPAs patients are referred to sur...

ea0049ep1080 | Pituitary - Clinical | ECE2017

20-year retrospective study of clinically non-functioning pituitary adenomas – a single center experience

Matta-Coelho Claudia , Almeida Rui , Marques Olinda

Background: Clinically non-functioning pituitary adenomas (NFPA) are the most common pituitary adenomas but their treatment remains challenging. Our aim is to describe clinical, imagiological and hormonal characteristics of patients with NFPA presenting at our department.Methods: Retrospective review of medical records of patients with NFPA at our centre from 1996 to 2016. Exclusion criteria: prolactin >100 ng/ml or histologic evidence of prolactinom...

ea0037ep1242 | Clinical Cases–Pituitary/Adrenal | ECE2015

Hypopituitarism after miscarriage: a case report

Monteiro Ana Margarida , Alves Marta , Marques Olinda

Introduction: Sheehan’s syndrome (SS) is a cause of partial or total hypopituitarism that occurs after postpartum pituitary infarction, in the context of serious bleeding and/or hypotension. With the advancement of obstetric care, it has become a rare disease in developed countries, but its prevalence may be underestimated. Clinical presentation is dependent on the severity of hormonal deficits, is often nonspecific and many women may be asymptomatic for years. These reas...

ea0037ep1320 | Clinical Cases–Thyroid/Other | ECE2015

Hyperprolactinemia and Leydig cell tumor

Monteiro Ana Margarida , Alves Marta , Marques Olinda

Introduction: Leydig cell tumors are the most common testicular sex cord stromal tumors. The most frequent clinical presentation is a testicular mass. However, they can present with endocrine manifestations, and gynecomastia is the most common presentation. Hyperprolactinemia can cause hypogonadotropic hypogonadism, and in males, is also a cause of gynecomastia.Clinical case: A 24-years-old male was referred to our Endocrinology Department due to hyperpr...

ea0035p926 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pituitary apoplexy: surgical or conservative management

Sousa Duarte , Marques Olinda , Almeida Rui

Objectives: The rarity of pituitary apoplexy renders it a difficult subject for audit; hence there are no evidence-based standards of optimum care for such patients. The main controversy in management relates to the role of acute surgical intervention. Recently, a more conservative management has been adopted towards patients presenting with this condition. Therefore, it is important to evaluate the differences in outcome between patients submitted to surgical and conservative...

ea0032p890 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Macroprolactinomas: dopamine agonists for how long?

Santos Maria Joana , Almeida Rui , Marques Olinda

Introduction: Generously supported by IPSEN)-->Dopamine agonists (DA) effectively normalize prolactin secretion and reduce tumour size in most patients with macroprolactinomas. However, some patients are considered partially/totally resistant. Some authors propose that patients treated for 2 years, with normal prolactin secretion with low dose AD and maximal tumour diameter reduction >50%, could suspend treatment, but relapse rat...

ea0032p948 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Effect of somatotropin and IGF1 secretion on glucose metabolism: diabetic ketoacidosis as first manifestation of acromegaly

Santos Maria Joana , Almeida Rui , Marques Olinda

Generously supported by IPSEN)-->Insulin and somatotropin (GH) have opposite effects in glucose metabolism. GH increases the production of glucose through lypolisis and inhibits hepatic and peripheric neoglucogenesis induced by insulin. When insulin secretion is insufficient to overcome insulin resistance, intolerance to glucose or diabetes appears. Drugs used in the treatment of acromegaly also influence glucose metabolism: SSA decr...

ea0056p721 | Clinical case reports - Pituitary/Adrenal | ECE2018

Late onset adrenocorticotrope deficiency in combined pituitary hormone deficiency caused by a mutation of the PROP1 gene

Paredes Silvia , Marques Olinda , Alves Marta

Introduction: PROP1-related combined pituitary hormone deficiency (CPHD) is associated with deficiencies of growth hormone (GH); thyroid-stimulating hormone (TSH); gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH); prolactin (PRL); and occasionally adrenocorticotropic hormone (ACTH).Clinical case: We report a clinical case of a progressive CPHD in a man presenting with first symptoms of hypocortisolism at the age of 75 years....

ea0073aep562 | Pituitary and Neuroendocrinology | ECE2021

Cognitive impairment, obesity, and hypopituitarism - several entities or one syndrome?

Juliana Marques-Sá , Joana Santos Maria

IntroductionPrader-Willi syndrome (PWS) is a multisystemic genetic disorder caused by lack of expression of genes on the paternally inherited chromosome 15q11.2-q13 region. Despite PWS present manifestations from birth, affected individuals can remain undiagnosed until adulthood.Clinical caseWoman, 40 years old, with cognitive impairment, referred to endocrinology due to morbid obesity (BMI 44.5 Kg/m2</s...

ea0090ep83 | Adrenal and Cardiovascular Endocrinology | ECE2023

Primary adrenal insufficiency in the context of small-cell neuroendocrine prostate cancer

de Brito Marques Francisca , Magalhaes Helena , Ferreira Joana Lima , de Carvalho Francisco Simoes , Marques Ana Paula

Introduction: The small-cell neuroendocrine prostate carcinoma (SCPC) is rare, highly aggressive and usually transforms from prostate adenocarcinoma (PAC) after androgen deprivation therapy (ADT).Case Report: A 66-year-old man had a three-year history of high-grade PAC with high burden disease (abdominal lymph node and bone metastasis) at presentation (09/2019). On the initial staging evaluation, the CT scan documented a 20 mm left adrenal nodule compati...